pharma-and-clinical-pharmacy-congress-2016

Notes:

Page 62

Pharma & Clinical Pharmacy Congress 2016

November 07-09, 2016

Volume 5 Issue 4(Suppl)

Clin Pharmacol Biopharm

ISSN: 2167-065X CPB, an open access journal

conferenceseries

.com

November 07-09, 2016 Las Vegas, Nevada, USA

International

Pharma & Clinical Pharmacy Congress

Oztekin Algul, Clin Pharmacol Biopharm 2016, 5:4(Suppl)

Investigations on structure-activity relationships and anti-proliferative activities of some bis-

benzimidazole derivatives

Oztekin Algul

Mersin University, Turkey

s cancer chemotherapy has not yet reached the desired level, intensive studies are continue to develop more potent, more

selective and less toxic novel anticancer drugs. In anticancer drug development studies, the effect of novel compounds

on apoptotic and anti-apoptotic gene expressions is very important. In our preliminary studies, a series of 2-substituted

benzimidazole derivatives were synthesized and tested for their cytotoxic effect against leukemic cell lines. These compounds

were particularly found to be quite selective against the hepatocellular carcinoma cell line. Then, the effect of bis-benzimidazol

derivative compounds on apoptosis and their mechanism of action were investigated in hepatocellular carcinoma in rats. In this

study, anti-proliferative activities of twelve bis-benzimidazole derivatives was evaluated. The synthesized bis-benzimidazole

derivatives was to determine the potency and specificity against five different cancer cells [Human Lung Adenocarcinoma

Epithelial Cells (A549), Human Renal Cancer Cells (A498), Human Cervical Cancer cells (HeLa), Human Skin Malignant

Melanoma Cells (A375), Human Hepatocellular Carcinoma Cells (HepG2) lines] compared to methotrexate (MTX). In

conclusion, bis-benzimidazole derivatives exhibited higher anti-proliferative than 2-substituted benzimidazoles.

Biography

Oztekin Algul has completed his PhD from Gazi University/Turkey in 2000 and Post-doctoral studies from Saarland Universitey/Germany and Connecticut

University/USA School of Pharmacy. He has been the Head of Deparment of Pharmaceutical Chemistry in Mersin University/Turkey since 2002.